Explore all subjects

The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Psychiatrists (US)

February 5, 2008
Doxepin is new again
By a GLG Expert Contributor
Analysis of: Somaxon Pharmaceuticals Submits New Drug Application For SILENOR(TM) For The Treatment Of Insomnia (www.pipelinereview.com)
Doxepin was developed as an antidepressant nearly 40 years ago.  It has been used by generations of psychiatrists for its sedating and sleep promoting actions, much as many other of the sedating antidepressants of yore.  Now it is being developed as a treatment of insomnia--the one twist is...
January 29, 2008
How do we like our drug reps? Nothing new here but the reps' problems are increasing.
By a GLG Expert Contributor
Analysis of: 19 Percent of Office-Based Physicians Refuse to See Pharmaceutical, Biotech and Medical Device Sales Reps (www.drugs.com)
This article is important primarily to those companies and reps who do not pay attention.  Doctors are human and will be most pleased to see those reps who comply with the physician's stated needs.  If the days or hours are limited or an appointment required, the reps need to stay within those...
January 23, 2008
Novel Antidepressant Agent Tyrima(TM) has Real Potential But Efficacy Not Fully Evaluated
By a GLG Expert Contributor
Analysis of: CeNeRx BioPharma Announces Successful Completion of Phase l Clinical Program for Novel Antidepressant Agent Tyrima(TM) (www.pipelinereview.com)
MAOI's really work very well in patients in whom tricyclic and newer and safer variations of the theme (blockade of norepinephrine, serotonin, and dopamine uptake) do not.  It is about time that the focus has shifted to a safer version of MAOIs, the selective and reversible novel class of drugs...
January 11, 2008
Cialis for Boy Scouts
By a GLG Expert Contributor
Analysis of: Cialis Is Cleared for Daily Use (online.wsj.com)
The notion that Lilly is promulgating here by marketing Cialis as a daily preparation is that you can have it both ways, namely always being prepared for sexual relations that are spontaneous.  From an observer of the human comedy (me), this will sell very well as the Baby Boom ages.  No mention...
January 9, 2008
Not Another mGluR Drug: The Competition Is On.
By a GLG Expert Contributor
Analysis of: Pfizer and Taisho Finalize Agreement for Novel Schizophrenia Drug Candidate (www.pipelinereview.com:80)
Pfizer Inc (NYSE:PFE) and Taisho Pharmaceutical Co., Ltd. (OTC:TSOPF.PK) announced the signing of a definitive agreement for worldwide collaboration to research, develop and commercialize TS-032.   TS-032 is a metabotropic glutamate receptor (mGluR) agonist, a novel drug candidate for the...
January 8, 2008
If we view business interest as an indicator of efficacy glutamate-based treatment of schizophrenia is a success
By a GLG Expert Contributor
Analysis of: Addex and Merck & Co., Inc. Enter License Agreement to Develop a Drug Candidate for Schizophrenia (www.pipelinereview.com:80)
Allosteric modulation of the metabotropic glutamate receptor 5 (mGluR5) for treatment of schizophrenia seems highly promising from a basic science perspective.  It has not been well tested in the clinic yet.  The fact that two major pharmaceutical firms are now in the hunt towards clinical...
January 8, 2008
Merck’s Agreement With Addex To Develop ADX63365: Eli Lilly May Have Competition In Groundbreaking Glutamate-Based Treatment of Schizophrenia.
By a GLG Expert Contributor
Analysis of: Addex and Merck & Co., Inc. Enter License Agreement to Develop a Drug Candidate for Schizophrenia (www.pipelinereview.com:80)
Addex Pharmaceuticals (Swiss:ADXN.SW) announced on January 3, 2008 an exclusive worldwide license agreement with Merck & Co., Inc. (NYSE:MRK) to develop ADX63365, a potent and selective positive allosteric modulator of the metabotropic glutamate receptor subtype 5 (mGluR5) with potential for the...
January 3, 2008
Serotonin and satiety is very interesting
By a GLG Expert Contributor
Analysis of: Biovitrum has Successfully Completed the First Phase I Trial of its 5-HT6 Receptor Antagonist (BVT.74316) (www.pipelinereview.com)
An interesting observation made as a consequence of the widespread use of serotonin specific reuptake inhibitors (SSRI) in clinical psychiatry is that these medications tend to affect appetite.  SSRIs can cause either weight gain or loss.  There was a time when they were extensively used in...
December 28, 2007
Would you be excited if I told you I had a new model car?
By a GLG Expert Contributor
Analysis of: Lu AA21004 for the treatment of mood and anxiety disorders enters into clinical phase III (www.pipelinereview.com)
Lu AA21004 is a new "bis-aryl-sulphanyl modulator" that has both preclinical and clinical support for future development for market as an "affective modulator". (I use the term affective modulator because I doubt whether the ultimate indication for this agent will be based on anxiety or depression.) ...
December 26, 2007
Cymbalta (Eli Lilly: LLY) Gets FDA Seal of Approval for Long-term Depression Management
By a GLG Expert Contributor
Analysis of: FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder (www.prnewswire.com)
Cymbalta (Eli Lilly: LLY) solidifies its place in the depression marketplace with this new FDA approval for maintenance treatment.  The incrementaL impact on sales is another matter.

Previous Page : 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 Next71 to 80 of 405

Analytics


Generated at 2009-01-09T13:00:20.343